VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not demonstrated significant clinical benefit in patients with prostate cancer. To identify additional immune inhibitory pathways in the prostate tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors fr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Nat Med
Autori principali: Gao, Jianjun, Ward, John F, Pettaway, Curtis A, Shi, Lewis Z, Subudhi, Sumit K, Vence, Luis M, Zhao, Hao, Chen, Jianfeng, Chen, Hong, Efstathiou, Eleni, Troncoso, Patricia, Allison, James P, Logothetis, Christopher J, Wistuba, Ignacio I, Sepulveda, Manuel A, Sun, Jingjing, Wargo, Jennifer, Blando, Jorge, Sharma, Padmanee
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5466900/
https://ncbi.nlm.nih.gov/pubmed/28346412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4308
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi